August 18, 2009 (FinancialWire) — Cellceutix Corp. (OTCBB: CTIX), a bio-pharmaceutical company in the business of developing small-molecule therapies in areas of unmet medical needs, has signed an agreement with Girindus America, Inc., for the manufacture of Kevetrin active pharmaceutical ingredient. Terms of the agreement were not disclosed.

“This is a big step toward our short-term goal of filing for an investigational new drug exemption with the FDA,” said George Evans, CEO of Cellceutix. “We will use the material manufactured by Girindus to do the last animal studies needed for the filing of an IND, as well as for phase 1 human trials. We think Girindus will be an excellent partner for Cellceutix.”

Kevetrin is being developed to treat certain cancers. The company has recently reported encouraging results in animal models of drug resistant lung cancers. For more information about these results, please visit the Cellceutix web site at www.cellceutix.com.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.